News

OrbusNeich Medical noted that it has identified unlicensed use by Boston Scientific of certain technologies protected under US Patent No 7,682,384 B2. As the owner by assignment of

T-DM1 comprises ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group. T-DM1 is in global

Granisetron is expected to be made available in 0.1mg per ml and 1.0mg per ml single-dose vials, and 4.0mg per 4ml multi-dose vials. Sagent expects to begin marketing

Atlas Operations is conducting a voluntary recall after being informed by the FDA that lab analyses found that the products to contain Sulfoaildenafil, an analogue of Sildenafil, an

The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios’ innovative cancer metabolism research platform.

These data indicate that, if clinically validated, VGX-100 has the potential to be a useful new treatment for some types of cancer. VGX-100 is a fully human monoclonal

The agreement provides Ivax Diagnostics the rights for Diamedix and Delta Biologicals subsidiaries to distribute Biomerica’s suite of products which includes 33 ELISA (Enzyme-Linked Immunosorbent Assay) test kits

Required for FDA new drug application (NDA) submission, this combination rule study – comparing the efficacy and safety profiles of MoxDuoIR against component doses of morphine and oxycodone

NiKem Research claimed that it has provided high quality cost-effective bioanalytical support both for its in-vitro ADME and in-vivo PK services associated to various drug discovery programs and